Developer docs
API playgroundTry for free, no card

Search company profiles

NeuMedics

Full company profile

uuid000f7cg

Namestring
NeuMedics
Legal namestring
NeuMedics Inc.
Websiteurl
neumedics.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

NeuMedics Inc. is an early-stage, privately held biopharmaceutical company developing NM320, a first-in-class topical eye-drop therapy for retinal disease. The lead indication is dry age-related macular degeneration (AMD), with diabetic retinopathy and other oxidative-stress-driven retinal conditions positioned as follow-on opportunities. The company was formed in 2008 in Washington State and now operates from a New York headquarters; it remains sub-scale at 1–10 employees and is led by a small executive team headed by CEO William D. Schwieterman, M.D., with Mark L. Nelson, Ph.D. as VP of Chemistry and Iain Duncan as COO.

NM320 is built on a modified tetracycline scaffold derived from minocycline, combined with a proprietary lipophilic microemulsion formulation designed to deliver therapeutic drug levels to the posterior retina without intravitreal injection. The mechanism targets mitochondrial dysfunction and oxidative stress in retinal pigment epithelial cells, aiming to intervene before irreversible degeneration rather than treating late-stage disease symptomatically. Preclinical work has demonstrated retinal pigment epithelial cell protection in an AMD mouse model with topical administration, but no human clinical efficacy data is disclosed in the source material.

NeuMedics is pre-revenue and intends to monetize through pharmaceutical licensing, co-development, or royalty arrangements rather than independent commercialization. The company's GTM motion is enterprise partnership outreach to larger pharma companies willing to advance NM320 through clinical development and eventual market launch. Capitalization is thin: the only disclosed funding event is a $87,950 financing in May 2009, with no institutional investors, parent company, or recent venture rounds identified in the source data, leaving the company's near-term clinical progression contingent on a future partnership or financing transaction.

Short descriptiontext

NeuMedics is an early-stage, pre-revenue biopharmaceutical company developing NM320, a first-in-class modified-tetracycline topical eye drop for dry AMD and related retinal diseases, intended to be advanced via pharmaceutical licensing or co-development partnerships rather than independent commercialization.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal disease therapeutics, topical ophthalmic drugs, tetracycline-based therapeutics, ocular drug delivery, biopharmaceutical drug development
Industry2 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Ophthalmic Goods3851
Product category
Ophthalmic Pharmaceuticals / Retinal Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical licensing/partnerships
TypeLicensing Royalties
Description

Pre-revenue biotech company. Revenue model will likely involve licensing NM320 to larger pharmaceutical companies for clinical development and commercialization, or co-development partnerships.

neumedics.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NM320
Description

A first-in-class, tetracycline-based, retinal therapy designed to protect cells before irreversible degeneration. Derived from minocycline, NM320 is a topical eye drop therapy for dry age-related macular degeneration (AMD) that delivers therapeutic drug levels to the retina without injections.

neumedics.com
Core offering1 text field

NeuMedics develops NM320, a first-in-class topical eye drop therapy for retinal diseases—primarily dry age-related macular degeneration (AMD)—built on a modified tetracycline scaffold combined with a proprietary lipophilic microemulsion delivery system. The therapy is designed to deliver therapeutic drug levels to the posterior retina without intravitreal injections, targeting mitochondrial dysfunction and oxidative stress to protect retinal cells before irreversible degeneration.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Preclinical evidence of retinal pigment epithelial cell protection in established AMD mouse model with topical administration
Product overview1 text field

NeuMedics is an early-stage biotechnology company developing a single core product, NM320, a first-in-class topical eye drop therapy for retinal diseases, particularly dry age-related macular degeneration. NM320 is built on a proprietary platform combining a modified tetracycline scaffold with a lipophilic microemulsion delivery system designed to deliver therapeutic drug levels to the retina without injections. The company's focus is on intervening early in disease progression by targeting mitochondrial dysfunction and oxidative stress at the cellular level.

Product and service1 record
1NM320
CategoryOphthalmic Pharmaceuticals / Retinal Therapeutics
Description

NM320 is a first-in-class, tetracycline-based retinal therapy derived from minocycline, delivered as a topical eye drop via a proprietary lipophilic microemulsion. It is designed to stabilize mitochondrial dysfunction, reduce oxidative stress, and protect retinal cells before irreversible degeneration in dry age-related macular degeneration (AMD), with broader potential in diabetic retinopathy and other retinal diseases driven by oxidative stress.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Apellis developed and commercialized Syfovre (pegcetacoplan), the first FDA-approved therapy for geographic atrophy secondary to dry AMD. It is the most directly comparable late-stage retinal-degeneration peer and serves as a benchmark for regulatory pathway, commercial dynamics, and competitive positioning versus NM320.

TypeDirect peer
Description

Iveric Bio developed Izervay (avacincaptad pegol), FDA-approved for geographic atrophy in dry AMD and acquired by Astellas in 2023. Direct clinical and commercial peer for the same indication NeuMedics targets, providing useful read-throughs on partnership economics and label dynamics.

TypeDirect peer
Description

Annexon is developing ANX007, an investigational therapy for geographic atrophy and other retinal neurodegenerative diseases, with a neuroprotective mechanism comparable in spirit to NM320's upstream targeting approach. Comparable size and clinical-stage profile make it a useful benchmarking peer.

TypeDirect peer
Description

Alkeus is developing gildeuretinol (ALK-001) for Stargardt disease and exploring age-related macular degeneration, with a focus on reducing toxic vitamin A dimers implicated in retinal degeneration. Comparable emerging retinal-disease developer with a non-injection therapeutic angle.

TypeEmerging player
Description

Lineage is developing OpRegen, an allogeneic retinal pigment epithelium cell therapy for dry AMD with geographic atrophy. Although cell-therapy based rather than small molecule, it is targeting the same unmet need and provides a useful read on emerging modalities competing with NM320.

TypeEmerging player
Description

Aldeyra is developing reproxalap and other small-molecule therapies for ocular inflammatory conditions including dry eye disease, with adjacencies to retinal indications. Comparable small-cap, small-molecule ophthalmology developer using non-invasive topical approaches.

TypeBroad incumbent
Description

Regeneron markets Eylea (aflibercept), the leading intravitreal anti-VEGF therapy for wet AMD, diabetic retinopathy, and related retinal conditions. As the dominant incumbent in the retinal injection market, Eylea defines the standard-of-care NM320 aims to disrupt with non-invasive delivery.

TypeBroad incumbent
Description

Genentech markets Lucentis (ranibizumab) and Vabysmo (faricimab), foundational anti-VEGF therapies for wet AMD and diabetic eye disease. Represents the established large-pharma competitive backdrop against which NM320's differentiated mechanism and delivery must compete.

TypeEmerging player
Description

Ocular Therapeutix develops sustained-release ophthalmic drug delivery technologies (e.g., Dextenza, OTX-TKI) targeting retinal and anterior-segment diseases. Most relevant peer for novel drug-delivery approaches in ophthalmology, sharing NeuMedics' focus on reducing treatment burden versus conventional delivery.

TypeDirect peer
Description

Kodiak Sciences developed tarcocimab (KSI-301), an anti-VEGF therapy for retinal vascular diseases, with a focus on durability and reduced injection burden. Direct peer in targeting retinal diseases with novel mechanisms aiming to displace the intravitreal injection paradigm.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuMedics

Ophthalmic Pharmaceuticals / Retinal Disease Therapeuticsneumedics.com

NeuMedics is an early-stage, pre-revenue biopharmaceutical company developing NM320, a first-in-class modified-tetracycline topical eye drop for dry AMD and related retinal diseases, intended to be advanced via pharmaceutical licensing or co-development partnerships rather than independent commercialization.

What NeuMedics does

NeuMedics Inc. is an early-stage, privately held biopharmaceutical company developing NM320, a first-in-class topical eye-drop therapy for retinal disease. The lead indication is dry age-related macular degeneration (AMD), with diabetic retinopathy and other oxidative-stress-driven retinal conditions positioned as follow-on opportunities. The company was formed in 2008 in Washington State and now operates from a New York headquarters; it remains sub-scale at 1–10 employees and is led by a small executive team headed by CEO William D. Schwieterman, M.D., with Mark L. Nelson, Ph.D. as VP of Chemistry and Iain Duncan as COO.

NM320 is built on a modified tetracycline scaffold derived from minocycline, combined with a proprietary lipophilic microemulsion formulation designed to deliver therapeutic drug levels to the posterior retina without intravitreal injection. The mechanism targets mitochondrial dysfunction and oxidative stress in retinal pigment epithelial cells, aiming to intervene before irreversible degeneration rather than treating late-stage disease symptomatically. Preclinical work has demonstrated retinal pigment epithelial cell protection in an AMD mouse model with topical administration, but no human clinical efficacy data is disclosed in the source material.

NeuMedics is pre-revenue and intends to monetize through pharmaceutical licensing, co-development, or royalty arrangements rather than independent commercialization. The company's GTM motion is enterprise partnership outreach to larger pharma companies willing to advance NM320 through clinical development and eventual market launch. Capitalization is thin: the only disclosed funding event is a $87,950 financing in May 2009, with no institutional investors, parent company, or recent venture rounds identified in the source data, leaving the company's near-term clinical progression contingent on a future partnership or financing transaction.

NeuMedics firmographics

Firmographics
Name
NeuMedics
Legal name
NeuMedics Inc.
Website
https://neumedics.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuMedics is an early-stage, pre-revenue biopharmaceutical company developing NM320, a first-in-class modified-tetracycline topical eye drop for dry AMD and related retinal diseases, intended to be advanced via pharmaceutical licensing or co-development partnerships rather than independent commercialization.
Ownership category
akta.pro rank

NeuMedics industry classification

Industry
Product category
Ophthalmic Pharmaceuticals / Retinal Disease Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKAKAE
Retina & Vitreous Specialists

Keywords

  • Retinal disease therapeutics
  • Topical ophthalmic drugs
  • Tetracycline-based therapeutics
  • Ocular drug delivery
  • Biopharmaceutical drug development

Where NeuMedics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuMedics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical licensing/partnerships: Pre-revenue biotech company. Revenue model will likely involve licensing NM320 to larger pharmaceutical companies for clinical development and commercialization, or co-development partnerships.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

NeuMedics product offering

Product offering

Core offering

NeuMedics develops NM320, a first-in-class topical eye drop therapy for retinal diseases—primarily dry age-related macular degeneration (AMD)—built on a modified tetracycline scaffold combined with a proprietary lipophilic microemulsion delivery system. The therapy is designed to deliver therapeutic drug levels to the posterior retina without intravitreal injections, targeting mitochondrial dysfunction and oxidative stress to protect retinal cells before irreversible degeneration.

Product overview

NeuMedics is an early-stage biotechnology company developing a single core product, NM320, a first-in-class topical eye drop therapy for retinal diseases, particularly dry age-related macular degeneration. NM320 is built on a proprietary platform combining a modified tetracycline scaffold with a lipophilic microemulsion delivery system designed to deliver therapeutic drug levels to the retina without injections. The company's focus is on intervening early in disease progression by targeting mitochondrial dysfunction and oxidative stress at the cellular level.

Differentiator

Problem solved

Functional benefit

Brands

  • NM320: A first-in-class, tetracycline-based, retinal therapy designed to protect cells before irreversible degeneration. Derived from minocycline, NM320 is a topical eye drop therapy for dry age-related macular degeneration (AMD) that delivers therapeutic drug levels to the retina without injections.

Products and services

  • NM320 NM320 is a first-in-class, tetracycline-based retinal therapy derived from minocycline, delivered as a topical eye drop via a proprietary lipophilic microemulsion. It is designed to stabilize mitochondrial dysfunction, reduce oxidative stress, and protect retinal cells before irreversible degeneration in dry age-related macular degeneration (AMD), with broader potential in diabetic retinopathy and other retinal diseases driven by oxidative stress.

Quantifiable outcome

  • Preclinical evidence of retinal pigment epithelial cell protection in established AMD mouse model with topical administration

Companies that use NeuMedics

Customer profile

Segments3 records

Ideal customer profiles1 record

NeuMedics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

NeuMedics partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights4 records

NeuMedics competitors and assessment

Company assessment

Direct peers

  • Apellis Pharmaceuticals: Apellis developed and commercialized Syfovre (pegcetacoplan), the first FDA-approved therapy for geographic atrophy secondary to dry AMD. It is the most directly comparable late-stage retinal-degeneration peer and serves as a benchmark for regulatory pathway, commercial dynamics, and competitive positioning versus NM320.
  • Iveric Bio (Astellas): Iveric Bio developed Izervay (avacincaptad pegol), FDA-approved for geographic atrophy in dry AMD and acquired by Astellas in 2023. Direct clinical and commercial peer for the same indication NeuMedics targets, providing useful read-throughs on partnership economics and label dynamics.
  • Annexon, Inc. Annexon is developing ANX007, an investigational therapy for geographic atrophy and other retinal neurodegenerative diseases, with a neuroprotective mechanism comparable in spirit to NM320's upstream targeting approach. Comparable size and clinical-stage profile make it a useful benchmarking peer.
  • Alkeus Pharmaceuticals: Alkeus is developing gildeuretinol (ALK-001) for Stargardt disease and exploring age-related macular degeneration, with a focus on reducing toxic vitamin A dimers implicated in retinal degeneration. Comparable emerging retinal-disease developer with a non-injection therapeutic angle.
  • Kodiak Sciences: Kodiak Sciences developed tarcocimab (KSI-301), an anti-VEGF therapy for retinal vascular diseases, with a focus on durability and reduced injection burden. Direct peer in targeting retinal diseases with novel mechanisms aiming to displace the intravitreal injection paradigm.

Emerging players

  • Lineage Cell Therapeutics: Lineage is developing OpRegen, an allogeneic retinal pigment epithelium cell therapy for dry AMD with geographic atrophy. Although cell-therapy based rather than small molecule, it is targeting the same unmet need and provides a useful read on emerging modalities competing with NM320.
  • Aldeyra Therapeutics: Aldeyra is developing reproxalap and other small-molecule therapies for ocular inflammatory conditions including dry eye disease, with adjacencies to retinal indications. Comparable small-cap, small-molecule ophthalmology developer using non-invasive topical approaches.
  • Ocular Therapeutix: Ocular Therapeutix develops sustained-release ophthalmic drug delivery technologies (e.g., Dextenza, OTX-TKI) targeting retinal and anterior-segment diseases. Most relevant peer for novel drug-delivery approaches in ophthalmology, sharing NeuMedics' focus on reducing treatment burden versus conventional delivery.

Broad incumbents

  • Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the leading intravitreal anti-VEGF therapy for wet AMD, diabetic retinopathy, and related retinal conditions. As the dominant incumbent in the retinal injection market, Eylea defines the standard-of-care NM320 aims to disrupt with non-invasive delivery.
  • Genentech (Roche): Genentech markets Lucentis (ranibizumab) and Vabysmo (faricimab), foundational anti-VEGF therapies for wet AMD and diabetic eye disease. Represents the established large-pharma competitive backdrop against which NM320's differentiated mechanism and delivery must compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

NeuMedics social profiles

Digital presence

NeuMedics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuMedics leadership team

Management profile

Number of profiles

Profiles3 records

NeuMedics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuMedics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuMedics

What does NeuMedics do?

NeuMedics develops NM320, a first-in-class topical eye drop therapy for retinal diseases—primarily dry age-related macular degeneration (AMD)—built on a modified tetracycline scaffold combined with a proprietary lipophilic microemulsion delivery system. The therapy is designed to deliver therapeutic drug levels to the posterior retina without intravitreal injections, targeting mitochondrial dysfunction and oxidative stress to protect retinal cells before irreversible degeneration.

Is NeuMedics a public or private company?

NeuMedics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NeuMedics founded?

NeuMedics was founded in 2008. It employs 11 to 50 people.

Where is NeuMedics based?

NeuMedics is headquartered in Seattle, United States, in the North America region.

How does NeuMedics make money?

One revenue line is on record: pharmaceutical licensing/partnerships.

Who are NeuMedics's main competitors?

Direct peers on record are Apellis Pharmaceuticals, Iveric Bio (Astellas), Annexon, Inc., Alkeus Pharmaceuticals and Kodiak Sciences. Emerging players are Lineage Cell Therapeutics, Aldeyra Therapeutics and Ocular Therapeutix. Broad incumbents are Regeneron Pharmaceuticals and Genentech (Roche).

Does NeuMedics have an API?

No public API is recorded for NeuMedics.

What industry is NeuMedics in?

NeuMedics's product category is Ophthalmic Pharmaceuticals / Retinal Disease Therapeutics. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAKAKAE, Retina & Vitreous Specialists. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales